Daxor Corporation Closes Q4 2023 With Growth In New Sales To Hospital Systems And Increased Utilization Of Its BVA-100 Blood Volume Diagnostic Across The U.S. At Existing Accounts

Author: Benzinga Newsdesk | February 07, 2024 09:06am

Daxor's ezBVA Lab Service Plays a Significant Role in Driving Growth and Fostering Widespread Adoption

 

Oak Ridge, TN, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) through new analyzer purchases and the utilization of Daxor's ezBVA Lab service. These Q4 2023 initiatives have all played a significant role in driving the growth and the widespread adoption of BVA providing a strong position going into 2024.

Q4-2023 sales wins include:

• BVA analyzer purchase at the largest and most integrated healthcare system in Georgia
• BVA analyzer purchase at a community-directed health system based in Wisconsin
• BVA analyzer rental at an academic health center servicing patients from Oregon, southwest Washington, Idaho, Montana, Alaska, and northern California
• Daxor's ezBVA Lab service extended to an additional site in a 17-hospital healthcare organization in New Jersey

"Our primary focus continues to be broadening our commercial reach by integrating with new hospital systems, exploring additional treatment areas, and continually strengthening the clinical and health economic evidence that demonstrates the benefits of our diagnostic," said Michael Feldschuh, Daxor's CEO and President. "Thanks to the unified efforts of our sales and marketing teams, we've significantly shortened our sales cycle and streamlined clinician onboarding, resulting in optimized care practices and ultimately, improved patient outcomes, all of which allowed us to end 2023 in a position of strength."

Posted In: DXR